Project Grant R16AI192054
Award Date 7/22/26
Completion Date 6/30/30
Dollars Obligated $193K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, DC 20059, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded George Washington University $781,999 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decipher mechanisms regulating the HLA-F and KIR3DS1 interaction in natural killer cells and HIV pathogenesis. The project, titled "Deciphering the Role of HLA-F and KIR3DS1 on NK Function and HIV Pathogenesis," focuses on understanding how the interaction between the KIR3DS1 receptor on NK...
- The National Institute of Allergy and Infectious Diseases awarded $427,626 to The Washington University on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify host factors that mediate nuclear retention of unspliced and partially spliced HIV-1 transcripts. The project will determine mechanisms by which intron-containing HIV-1 RNA molecules remain in the nucleus, contrasting with fully spliced viral messenger RNA that readily accesses host nuclear...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $757,880 on June 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the impact of HIV-1 5' leader defects on plasma viremia, proviral dynamics, and immune responses. The project addresses the mechanisms by which defective HIV proviruses with 5' leader region mutations persist despite antiretroviral therapy and evade immune-mediated killing. The research...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the Scripps Research Institute $937,343 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research optimizing vaccine-elicited cross-neutralizing antibody responses targeting the HIV envelope (Env) trimer apex to inform broadly neutralizing antibody (BnAb) development for...
- The National Institute of Allergy and Infectious Diseases awarded Western University of Health Sciences $144,000 on June 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how HIV accessory proteins VPU and NEF target the IPS-1 adaptor protein, leading to its degradation and inhibition of type I interferon production. The research examines the mechanism by which HIV manipulates the interferon system to evade immune detection and persist in the host,...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $791,065 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into the role of capsid interactions with viral RNA genome in assembly of HIV-1 cores. The research investigates how HIV-1 capsid proteins and viral RNA genome components organize during viral maturation. The study will clarify structural mechanisms underlying HIV-1 core formation,...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $781,073 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop interventions that silence HIV-1 and reduce viral reservoir persistence following antiretroviral therapy initiation. The research develops a new intervention using ectopic expression of an HIV-1-encoded antisense transcript (AST) delivered before ART initiation or restart. The work aims to...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $427,623 to The Washington University on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research dissecting how HIV-induced immunometabolic perturbation impairs tuberculosis control in people living with HIV despite effective antiretroviral therapy and viral suppression. The research...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $804,464 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research targeting the super elongation complex to regulate HIV transcription and latency. The research addresses HIV persistence in long-lived latent reservoirs that remain a major barrier to functional cure. The project focuses on developing small molecule regulators of viral transcription as...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine a Project Grant totaling $1,486,296 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the human antibody response to Cryptococcus neoformans and survival outcomes in HIV-associated cryptococcal meningoencephalitis, a devastating opportunistic infection of the central nervous system that occurs predominantly in people...